This approval is the most significant advancement in the treatment of CKD in over 20 years.
The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) that recommends AstraZeneca's Forxiga (dapagliflozin) for the treatment of adults with chronic kidney disease (CKD) as part of its marketing authorization. The FAD serves as the foundation for NICE's final guidance to the National Health Service (NHS). It's a move that will provide eligible patients with the first CKD treatment choice in nearly two decades. “I am thrilled by this decision from NICE, as this expanded recommendation is going to have a genuine impact on the way that kidney doctors and GPs can treat their patients,” said Professor James Burton, Professor of Renal Medicine and Honorary Consultant Nephrologist, University of Leicester.
CKD is a long-term condition in which the kidneys are unable to eliminate waste products from the body because they are not functioning properly. Tiredness, swollen ankles, feet, and hands, shortness of breath, and blood in the urine can occur in advanced stages of the condition. “For the first time in almost two decades, eligible people living with chronic kidney disease will have access to a new treatment option that has been shown to slow kidney decline and potentially delay transplant or dialysis. Given the impact those treatments can have on the quality of life of patients and those around them, this represents a significant milestone for many people living with kidney disease,” Professor Burton added.